Search

Author/Creator Lis, Joy

1. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Issue 8 (August 2015)

Authors:
Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentle...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 8(2015:Aug.)
Page Start:
908
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Issue 8 (August 2015)

Authors:
Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentle...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 8(2015:Aug.)
Page Start:
908
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search